Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

ABSTRACT: Pediatric regimens improve outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. End-consolidation (time point 2 [TP2]) minimal residual disease negativity (MRD^neg) is associated with improved survival. In this study, standard consolidation chemotherapy was replaced with blinatumomab to improve TP2 MRD^neg-a key survival surrogate in B-lineage ALL. From 2019 to 2022, 55 patients constituted the intention-to-treat (ITT) cohort, median age 25 (range, 16-39) years. Using a Simon's 2-stage design, blinatumomab replaced standard consolidation chemotherapy cycles with TP2 MRD^neg as the primary endpoint. Blinatumomab was associated with an improved TP2 MRD^neg rate of 70.8% (95% CI, 55.9%-83.0%) versus the null hypothes

SUBMITTER: Greenwood M 

PROVIDER: S-EPMC12828581 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature